

**Technology Appraisal Committee Meeting (Committee A)**  
**10 Spring Gardens, London SW1A 2BU**

**Minutes:** Confirmed

**Date and Time:** 16 October 2018, 10am- 5pm

<b>Present:</b>	1. Chair Jane Adam	Present for all notes
	2. Professor Iain Squire	Present for all notes
	3. Dr Steve Edwards	Present for Notes 11 to 27
	4. Dr Rita Faria	Present for all notes
	5. Ms Pamela Rees	Present for all notes
	6. Dr Brian Shine	Present for all notes
	7. Dr John Watkins	Present for all notes
	8. Dr Min Ven Teo	Present for all notes
	9. Dr Justin Daniels	Present for all notes
	10. Sumithra Maheswaran	Present for all notes
	11. Dr Mohit Sharma	Present for all notes
	12. Mrs Sarah Parry	Present for all notes
	13. Professor Olivia Wu	Present for all notes
	14. Dr Rachel Hobson	Present for all notes
	15. Mr Stephen Sharp	Present for all notes
	16. Dr Alice Turner	Present for all notes
	17. Dr Roger Whittaker	Present for all notes
	18. Dr Jeremy Braybrooke	Present for all notes

**In attendance:**

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Thomas Feist	Project Manager, National Institute for Health and Care Excellence.	Present for all notes

Marcia Miller	Technology Appraisal Administrator, National Institute for Health and Care Excellence	Present for all notes
Boglarka Mikudina	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 10
Zoe Charles	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 10
Juliet Kenny	Technical Analyst National Institute of Health and Care Excellence	Present for notes 19 to 27

**Non-public attendees:**

**ERG Team – BMJ-TAG**

Dr Steve Edwards	Director of Health Technology Assessment	Present for notes 1 to 8
Tracey Jhita	Health Economist	Present for notes 1 to 8
Charlotta Karner	Health Economist	Present for notes 1 to 8
Dr Peter Cain	Senior Health Economist	Present for notes 1 to 8
Vicky Wakefield		Present for notes 1 to 8

**ERG Team – Warwick Evidence**

Daniel Gallacher	Health Economist	Present for notes 11 to 16
Dr Chidoze Nduka	Health Economist	Present for notes 11 to 16

**Experts**

Alison Dejal	Patient expert, nominated by the Eve Appeal	Present for notes 1 to 8
Diane Cannon	Patient expert nominated by Melanoma UK	Present for notes 11 to 16
Dr Sadaf Ghaem-Maghami	Consultant Gynaecological Oncologist, RCOG	Present for notes 1 to 8

Professor Charlie Gourley	Chair of Medical Oncology and Honorary Consultant in Medical Oncology. Director, Nicola Murray Centre for Ovarian Cancer Research	Present for notes 1 to 8
Dr James Larkin	Consultant Medical Oncologist, Royal Marsden, nominated by BMS	Present for notes 11 to 16
Melanie Sturtevant	Patient expert nominated by Breast Cancer Now	Present for notes 19 to 23
Dr Sharon Tate	Head of Primary Care Development nominated by Target Ovarian Cancer	Present for notes 1 to 8
Dr Andrew Wardley	Consultant & MAHSC Honorary Chair in Breast Medical Oncology nominated by ROCHE	Present for notes 1 to 8 and 19 to 23

## Notes

### Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [ID1296]
2. Apologies were received from: Dr Graham Ash, Mr Adrian Griffin, Professor John McMurray, Dr Minal Bakhai and Dr Paul Robinson

### **Appraisal of Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [ID1296]**

#### **Part 1 – Open session**

3. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from AstraZeneca.
4. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.
  - 4.1. Dr Rita Faria declared a non-personal specific financial interest as she carried out some consultancy work back in 2014 in relation to the drug Olaparib.
    - 5.1.1 It was agreed that this declaration would not prevent participation in the meeting.
  - 4.2. Dr Alice Turner declared a non-personal specific financial interest as she received a research from the company for work in an unrelated field.
    - 5.2.1 It was agreed that this declaration would not prevent participation in the meeting.
5. The Chair introduced the lead team Dr Jeremy Braybrooke, Ms Pamela Rees and Mr Stephen Sharp, who gave presentations on the clinical effectiveness and cost effectiveness of **Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.**

6. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
7. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
8. The Chair then thanked the ERG representatives, experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

9. Discussion on confidential information continued. This information was supplied by the company.
  - 9.1. The committee decision was based on consensus.
10. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Appraisal of Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316]**

### **Part 1 – Open session**

11. The Chair welcomed the invited clinical and patient experts, evidence review group (ERG) representatives and representatives from AstraZeneca.
12. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests:
  - 12.1. No declaration of interests were made for the topic.
13. The Chair introduced the lead team, Professor Olivia Wu. Dr Jane Adam and Professor Olivia Wu gave a presentation on the clinical effectiveness and cost effectiveness of **Nivolumab for adjuvant treatment of resected stage III and IV melanoma**.
14. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
15. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

16. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

### **Part 2 – Closed session**

17. The committee decision was based on consensus.
18. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD)] in line with their decisions.

## **Appraisal of Pertuzumab for adjuvant treatment of early HER2-positive breast cancer [ID1192]**

### **Part 2 – closed session**

19. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from AstraZeneca.
20. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.
21. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
22. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
23. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

### **Part 2 – Closed session**

24. Discussion on confidential information continued. This information was supplied by the company.
25. The committee decision was based on consensus.
26. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD)] in line with their decisions.

### **Date, time and venue of the next meeting**

27. Thursday 15 November 2018, 10am at National Institute for Health and Care Excellence, 10 Spring Gardens, SW1A 2BU.